Crescent Biopharma
CBIO
31 hedge funds and large institutions have $77.4M invested in Crescent Biopharma in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 31 → 31 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
29% less capital invested
Capital invested by funds: $109M → $77.4M (-$32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$916K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$72.2K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$39K |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$23.8K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$23.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$228K |
| 2 |
Goldman Sachs
New York
|
-$143K |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$108K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$87.4K |
| 5 |
Renaissance Technologies
New York
|
-$83K |
CBIO Hedge Fund Activity: Q3 2015 in Review
31 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q3 2015, worth a combined $77.4M — down 29% from $109M a quarter earlier.
Fund positioning in CBIO was balanced in Q3 2015: 2 funds opened new positions, 2 closed out, 9 added to existing stakes and 10 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $916K. The largest seller was Franklin Resources, cutting an estimated $228K.
- 31 institutional investors held Crescent Biopharma (CBIO) as of Q3 2015, unchanged from Q2 2015.
- Funds reported $77.4M of Crescent Biopharma stock for Q3 2015, down 29% quarter-over-quarter.
- 2 funds opened new Crescent Biopharma positions in Q3 2015 and 2 closed out, a net change of 0 holders.
- The largest Crescent Biopharma buyer in Q3 2015 was Fidelity Investments, an estimated $916K added.
- The largest Crescent Biopharma seller in Q3 2015 was Franklin Resources, an estimated $228K sold.
Based on aggregated 13F filings for Q3 2015.